Funding
Funding for this research was provided by Eli Lilly and Company, IN, USA. TA Eyre reports consulting with BeiGene, Roche, AstraZeneca, Incyte, AbbVie, Gilead Sciences, Kite Pharma, Secura Bio, and Loxo@Lilly; receiving research funding from AstraZeneca and BeiGene; receiving honoraria from Roche, AstraZeneca, AbbVie and Gilead Sciences; Speaker’s Bureau for Roche, AstraZeneca, Incyte, AbbVie, Gilead Sciences, Kite Pharma, Loxo@Lilly, PeerView and Medscape; participating on a data safety monitoring or advisory board for BeiGene, Roche, AstraZeneca, Incyte, AbbVie, Gilead Sciences, Kite Pharma, Secura Bio and Loxo@Lilly; other for Loxo Oncology. NN Shah reports participating on a data safetymonitoring or advisory board for Novartis, Loxo@Lilly,Miltenyi Biotec, Kite Pharma, Bristol Myers Squibb, TG Therapeutics, Epizyme and Incyte; receiving research funding from Miltenyi Biotec; receiving honoraria from Loxo@Lilly; Speaker’s Bureau for Incyte. M Dreyling reports receiving research funding (institution) AbbVie, Bayer, Bristol Myers Squibb/Celgene, Gilead Sciences/Kite Pharma, Janssen and Roche; receiving honoraria from Amgen, AstraZeneca, Gilead Sciences/Kite Pharma, Janssen, Eli Lilly and Company, Novartis and Roche; participating on a data safety monitoring or advisory board for AstraZeneca, BeiGene, Bristol Myers Squibb/Celgene, Gilead Sciences/Kite Pharma, Janssen, Loxo@Lilly, Novartis, Roche. W Jurczak reports consulting with Janssen, AstraZeneca, MEI Pharma, Eli Lilly and Company, Takeda, Roche, AbbVie and BeiGene; receiving research funding from AbbVie, Bayer, BeiGene, Celgene, Janssen, Roche, Takeda, TG Therapeutics, AstraZeneca, MEI Pharma and Eli Lilly and Company. Y Wang reports receiving research funding from Incyte, InnoCare, Loxo@Lilly, Novartis, Genentech, MorphoSys, Genmab; receiving honoraria from Kite Pharma; participating on a data safety monitoring or advisory board for Eli Lilly and Company, TG Therapeutics, Loxo@Lilly, Incyte, InnoCare and Kit
